{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:58:30Z","timestamp":1780066710763,"version":"3.54.0"},"reference-count":65,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T00:00:00Z","timestamp":1750809600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background: Finasteride, a 5\u03b1-reductase inhibitor, is used for androgenetic alopecia and benign prostatic hyperplasia. However, concerns have emerged about its psychiatric side effects, including suicidality. This study analyzed finasteride-related reports from the FDA Adverse Event Reporting System (FAERS) to identify potential safety signals. Methods: Adverse events reported from 2015 to 2024 were extracted using preferred terms, quantified using Bayesian analysis and disproportionality metrics, including empirical Bayesian geometric mean (EBGM), information component (IC), reporting odds ratio (ROR), and proportional reporting ratio (PRR). Results: Most were male (87%), with 43% aged 18\u201340 years, primarily using finasteride for hair loss. Disproportionality metrics for suicidality-related events fluctuated between 2019 and 2024. In 2019, the ROR was 27.51 (95% CI: 23.22\u201332.58), the PRR was 21.96 (95% CI: 18.54\u201326.01), the EBGM was 20.50, and the IC was 4.36. A slight decline was observed in 2020, a surge in 2021, and a peak in 2022 (ROR 34.64 (95% CI: 28.36\u201341.88), PRR 27.82 (95% CI: 22.30\u201334.61), EBGM 24.96, IC 4.64). Although a sharp rise in suicidality reports was noted in 2024, the rates of ROR and PRR dropped to 19.04 (95% CI: 17.02\u201321.30) and 16.53 (95% CI: 14.78\u201318.50), respectively. Serious outcomes such as disability (18.7%), life-threatening events (12.9%), and death (7.5%) were also noted. Conclusions: The upward trend in suicidality-related safety signals among young male users since 2019, which peaked in 2024, reflects emerging safety concerns among finasteride users, reinforcing the need for pharmacovigilance. Collaborative action among healthcare professionals, regulatory authorities, and pharmaceutical companies, along with clear warnings and mental health assessments before and throughout finasteride therapy, can mitigate potential psychiatric risks and enhance patient safety.<\/jats:p>","DOI":"10.3390\/ph18070957","type":"journal-article","created":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T07:55:43Z","timestamp":1751442943000},"page":"957","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0793-5445","authenticated-orcid":false,"given":"Hilal A.","family":"Thaibah","sequence":"first","affiliation":[{"name":"Department of Clinical Practice, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"},{"name":"Pharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1669-2147","authenticated-orcid":false,"given":"Otilia J. F.","family":"Banji","sequence":"additional","affiliation":[{"name":"Department of Clinical Practice, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"},{"name":"Pharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3543-3872","authenticated-orcid":false,"given":"David","family":"Banji","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5866-8404","authenticated-orcid":false,"given":"Hadi A.","family":"Almansour","sequence":"additional","affiliation":[{"name":"Department of Clinical Practice, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"},{"name":"Pharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5630-2468","authenticated-orcid":false,"given":"Thamir M.","family":"Alshammari","sequence":"additional","affiliation":[{"name":"Department of Clinical Practice, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"},{"name":"Pharmacy Practice Research Unit, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Sullivan, M.J., and Geller, J. (2002). The effectiveness of reducing the daily dose of finasteride in men with benign prostatic hyperplasia. BMC Urol., 2.","DOI":"10.1186\/1471-2490-2-2"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1523-1747.2003.12167.x","article-title":"Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss)","volume":"8","author":"Shapiro","year":"2003","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_3","unstructured":"Polaris Market Research (2025, April 03). Finasteride Market Share, Size, Trends, Industry Analysis Report, by Product (1 mg, 5 mg); by Application; by Distribution Channel; by Region; Segment Forecast, 2024\u20132032. Available online: https:\/\/www.polarismarketresearch.com\/industry-analysis\/finasteride-market."},{"key":"ref_4","unstructured":"Salisbury, B.H., and Tadi, P. (2025). 5\u03b1-Reductase Inhibitors. StatPearls, StatPearls Publishing."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s13555-023-00974-4","article-title":"Use of 5-alpha reductase inhibitors in dermatology: A narrative review","volume":"13","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1111\/j.1743-6109.2012.02846.x","article-title":"Persistent sexual side effects of finasteride: Could they be permanent?","volume":"9","author":"Irwig","year":"2012","journal-title":"J. Sex Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e65434","DOI":"10.2196\/65434","article-title":"Explainable predictive model for suicidal ideation during COVID-19: Social media discourse study","volume":"27","author":"Bouktif","year":"2025","journal-title":"J. Med. Internet Res."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Seidler, Z.E., Wilson, M.J., Oliffe, J.L., Fisher, K., O\u2019Connor, R., Pirkis, J., and Rice, S.M. (2023). Suicidal ideation in men during COVID-19: An examination of protective factors. BMC Psychiatry, 23.","DOI":"10.1186\/s12888-023-04539-9"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jamadermatol.2020.3385","article-title":"Investigation of suicidality and psychological adverse events in patients treated with finasteride","volume":"157","author":"Nguyen","year":"2021","journal-title":"JAMA Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Laanani, M., Weill, A., Jollant, F., Zureik, M., and Dray-Spira, R. (2023). Suicidal risk associated with finasteride versus dutasteride among men treated for benign prostatic hyperplasia: Nationwide cohort study. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-32356-3"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamainternmed.2017.0089","article-title":"Association of suicidality and depression with 5\u03b1-reductase inhibitors","volume":"177","author":"Welk","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/bmb\/57.1.47","article-title":"Depression, suicide and deliberate self-harm in adolescence","volume":"57","author":"Harrington","year":"2001","journal-title":"Br. Med. Bull."},{"key":"ref_13","unstructured":"European Medicines Agency (2025, March 11). Meeting Highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 September\u20133 October 2024. Available online: https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-30-september-3-october-2024."},{"key":"ref_14","unstructured":"Medicines and Healthcare Products Regulatory Agency (2025, March 10). Men on Finasteride Asked to Stay Vigilant for Possible Psychiatric and Sexual Side Effects, Available online: https:\/\/www.gov.uk\/government\/news\/men-on-finasteride-asked-to-stay-vigilant-for-possible-psychiatric-and-sexual-side-effects."},{"key":"ref_15","unstructured":"Medicines and Healthcare Products Regulatory Agency (2025, March 09). Safety Review of Finasteride Public Assessment Report, Available online: https:\/\/assets.publishing.service.gov.uk\/media\/6630abd087bdbae4ab19adc9\/Finasteride_PAR_Accessible.pdf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/JCP.0000000000001379","article-title":"Risk of depression associated with finasteride treatment","volume":"41","author":"Pompili","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e420","DOI":"10.1002\/ski2.420","article-title":"The psychosocial impact of alopecia in men: A mixed-methods survey study","volume":"4","author":"Zucchelli","year":"2024","journal-title":"Skin Health Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1027\/1618-3169\/a000457","article-title":"Bald and bad?","volume":"66","author":"Kranz","year":"2019","journal-title":"Exp. Psychol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1111\/j.1523-1747.2003.12615.x","article-title":"Genetic basis of male pattern baldness","volume":"121","author":"Heath","year":"2003","journal-title":"J. Investig. Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ecl.2007.03.004","article-title":"Androgenetic alopecia","volume":"36","author":"Otberg","year":"2007","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_21","unstructured":"Public Citizen (2025, February 07). FDA Sued Over Inaction on Dangerous Hair Loss Medication Propecia. Available online: https:\/\/www.citizen.org\/news\/fda-sued-over-inaction-on-dangerous-hair-loss-medication-propecia\/."},{"key":"ref_22","unstructured":"Public Citizen (2025, February 09). Post-Finasteride Syndrome Foundation v. FDA. Available online: https:\/\/www.citizen.org\/litigation\/post-finasteride-syndrome-foundation-v-fda\/."},{"key":"ref_23","unstructured":"Post-Finasteride Foundation (2025, March 15). European Medicines Agency Initiates Finasteride-Safety Probe Focused Solely on Suicidality\u2014Which Could Lead to Label Changes, Market Suspension or Market Withdrawal in 30 Nations. Available online: https:\/\/www.pfsfoundation.org\/news\/european-medicines-agency-initiates-finasteride-safety-probe-focused-solely-on-suicidality-which-could-lead-to-label-changes-market-suspension-or-market-withdrawal-in-30-nations\/."},{"key":"ref_24","unstructured":"European Medicines Agency (2025, March 07). Finasteride- and Dutasteride-Containing Medicinal Products\u2014Referral. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/referrals\/finasteride-dutasteride-containing-medicinal-products."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s00345-020-03314-9","article-title":"An evaluation of the federal adverse events reporting system data on adverse effects of 5-alpha reductase inhibitors","volume":"39","author":"Harrell","year":"2021","journal-title":"World J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.fertnstert.2019.11.030","article-title":"Post-finasteride syndrome: A surmountable challenge for clinicians","volume":"113","author":"Traish","year":"2020","journal-title":"Fertil. Steril."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Jer\u00f3nimo, M.A., Pi\u00f1ar, S., Samos, P., Gonzalez, A.M., Bellsol\u00e0, M., Sabat\u00e9, A., Le\u00f3n, J., Aliart, X., Mart\u00edn, L.M., and Ace\u00f1a, R. (Rev. Psiquiatr. Salud Ment., 2021). Suicidal attempt and suicidal ideation during the COVID-19 pandemic compared to previous years, Rev. Psiquiatr. Salud Ment., Online ahead of print.","DOI":"10.1016\/j.rpsm.2021.11.004"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/13811118.2022.2051653","article-title":"Suicide risk in individuals with and without mental disorders before and during the COVID-19 pandemic: An analysis of three nationwide cross-sectional surveys in Czechia","volume":"27","author":"Kasal","year":"2023","journal-title":"Arch. Suicide Res."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Raifman, J., Ettman, C., Dean, L., Barry, C., and Galea, S. (2020). Economic precarity, social isolation, and suicidal ideation during the COVID-19 pandemic. PLoS ONE, 17.","DOI":"10.1101\/2020.10.05.20205955"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"102211","DOI":"10.1016\/j.janxdis.2020.102211","article-title":"How health anxiety influences responses to viral outbreaks like COVID-19: What all decision-makers, health authorities, and health care professionals need to know","volume":"71","author":"Asmundson","year":"2020","journal-title":"J. Anxiety Disord."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Flesia, L., Monaro, M., Mazza, C., Fietta, V., Colicino, E., Segatto, B., and Roma, P. (2020). Predicting perceived stress related to the COVID-19 outbreak through stable psychological traits and machine learning models. J. Clin. Med., 9.","DOI":"10.31234\/osf.io\/yb2h8"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4088\/JCP.12m07887","article-title":"Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects","volume":"73","author":"Irwig","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/phar.1612","article-title":"Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: A pharmacovigilance study","volume":"35","author":"Ali","year":"2015","journal-title":"Pharmacotherapy"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/CRT.1000273","article-title":"Long-term (10-year) efficacy of finasteride in 523 Japanese men with androgenetic alopecia","volume":"5","author":"Yanagisawa","year":"2019","journal-title":"Clin. Res. Trials"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Boero, G., Porcu, P., and Morrow, A.L. (2020). Pleiotropic actions of allopregnanolone underlie therapeutic benefits in stress-related disease. Neurobiol. Stress, 12.","DOI":"10.1016\/j.ynstr.2019.100203"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00213-013-3276-5","article-title":"Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: Regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability","volume":"230","author":"Carver","year":"2013","journal-title":"Psychopharmacology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1038\/s41467-023-40800-1","article-title":"Structural insights into opposing actions of neurosteroids on GABAA receptors","volume":"14","author":"Legesse","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.mehy.2012.02.009","article-title":"Glutamate-based depression GBD","volume":"78","author":"McCarthy","year":"2012","journal-title":"Med. Hypotheses"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s11930-018-0161-6","article-title":"The post-finasteride syndrome: Clinical manifestation of drug-induced epigenetics due to endocrine disruption","volume":"10","author":"Traish","year":"2018","journal-title":"Curr. Sex. Health Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"5430","DOI":"10.1038\/s41467-020-19249-z","article-title":"Structure of human steroid 5\u03b1-reductase 2 with the anti-androgen drug finasteride","volume":"11","author":"Xiao","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00213-005-0201-6","article-title":"Relevance of endogenous 3alpha-reduced neurosteroids to depression and antidepressant action","volume":"186","author":"Uzunova","year":"2006","journal-title":"Psychopharmacology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1038\/s44220-024-00325-y","article-title":"The neural connectome of suicidality in adults with mood and anxiety disorders","volume":"2","author":"Bryant","year":"2024","journal-title":"Nat. Ment. Health"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1111\/j.1743-6109.2007.00563.x","article-title":"Finasteride 5 mg and sexual side effects: How many of these are related to a nocebo phenomenon?","volume":"4","author":"Mondaini","year":"2007","journal-title":"J. Sex Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4103\/0378-6323.155573","article-title":"Nocebo effect in dermatology","volume":"81","author":"Sonthalia","year":"2015","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"113486","DOI":"10.1016\/j.psychres.2020.113486","article-title":"Psychological distress during the COVID-19 lockdown: The young adults most at risk","volume":"293","author":"Glowacz","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_47","unstructured":"World Health Organization (2025, March 10). Mental Health and COVID-19: Early Evidence of the Pandemic\u2019s Impact: Scientific Brief, 2 March 2022. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Sci_Brief-Mental_health-2022.1."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jad.2020.08.001","article-title":"Impact of COVID-19 pandemic on mental health in the general population: A systematic review","volume":"277","author":"Xiong","year":"2020","journal-title":"J. Affect. Disord."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/0018578719882323","article-title":"Existence of notoriety bias in FDA adverse event reporting system database and its impact on signal strength","volume":"56","author":"Neha","year":"2021","journal-title":"Hosp. Pharm."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2147\/CLEP.S4775","article-title":"Improving reporting of adverse drug reactions: Systematic review","volume":"1","author":"Molokhia","year":"2009","journal-title":"Clin. Epidemiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.abd.2020.02.001","article-title":"Post-finasteride syndrome","volume":"95","author":"Pereira","year":"2020","journal-title":"An. Bras. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"891","DOI":"10.2165\/00002018-200730100-00007","article-title":"Impact of safety alerts on measures of disproportionality in spontaneous reporting databases: The notoriety bias","volume":"30","author":"Pariente","year":"2007","journal-title":"Drug Saf."},{"key":"ref_53","first-page":"91","article-title":"Pharmacovigilance: Pharmacists\u2019 perspective on spontaneous adverse drug reaction reporting","volume":"6","author":"Hadi","year":"2017","journal-title":"Integr. Pharm. Res. Pract."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1210\/jc.2016-2726","article-title":"Characteristics of men who report persistent sexual symptoms after finasteride use for hair loss","volume":"101","author":"Basaria","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1111\/ajd.14380","article-title":"Re: The risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA): A population-based case-control study","volume":"65","author":"Chen","year":"2024","journal-title":"Australas. J. Dermatol."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Zhong, X., Yang, Y., Wei, S., and Liu, Y. (2025). Multidimensional assessment of adverse events of finasteride: A real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0309849"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.sapharm.2025.02.008","article-title":"Artificial intelligence (AI) in pharmacovigilance: A systematic review on predicting adverse drug reactions (ADR) in hospitalized patients","volume":"21","author":"Dsouza","year":"2025","journal-title":"Res. Soc. Adm. Pharm."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kim, J.V., Davis, S.E., Matheny, M.E., and Smith, J.C. (2024). Integrating electronic health records with other data sources for post-market drug safety signal identification: A review. Front. Drug Saf. Regul., 4.","DOI":"10.3389\/fdsfr.2024.1428831"},{"key":"ref_59","first-page":"CD012594","article-title":"Improving adverse drug event reporting by healthcare professionals","volume":"10","author":"Shalviri","year":"2024","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_60","unstructured":"Food and Drug Administration (2024, October 04). FDA Adverse Event Reporting System (FAERS) Quarterly Data Extract Files, Available online: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Alenzi, K.A., Alsuhaibani, D., Batarfi, B., and Alshammari, T.M. (2024). Pancreatitis with use of new diabetic medications: A real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1364110"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"803","DOI":"10.2147\/TCRM.S161148","article-title":"Signals of bleeding among direct-acting oral anticoagulant users compared to those among warfarin users: Analyses of the post-marketing FDA Adverse Event Reporting System (FAERS) database, 2010\u20132015","volume":"14","author":"Alshammari","year":"2018","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Khaleel, M.A., Khan, A.H., Ghadzi, S.M.S., Adnan, A.S., and Abdallah, Q.M. (2022). A standardized dataset of a spontaneous adverse event reporting system. Healthcare, 10.","DOI":"10.3390\/healthcare10030420"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"20420986231154075","DOI":"10.1177\/20420986231154075","article-title":"Association between proton pump inhibitors and rhabdomyolysis risk: A post-marketing surveillance using FDA adverse event reporting system (FAERS) database","volume":"14","author":"Altebainawi","year":"2023","journal-title":"Ther. Adv. Drug Saf."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Thaibah, H.A., Banji, O.J.F., Banji, D., and Alshammari, T.M. (2025). Diabetic ketoacidosis and the use of new hypoglycemic groups: Real-world evidence utilizing the food and drug administration adverse event reporting system. Pharmaceuticals, 18.","DOI":"10.3390\/ph18020214"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/957\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:58:28Z","timestamp":1760032708000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/7\/957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,25]]},"references-count":65,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["ph18070957"],"URL":"https:\/\/doi.org\/10.3390\/ph18070957","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,25]]}}}